Impaired SNX9 expression in immune cells during chronic inflammation: Prognostic and diagnostic implications

Journal of Immunology

Volumn 196, Issue 1, 2016, Pages 156-167

  Ish Shalom, Eliran ^a,b   Meirow, Yaron ^a   Sade Feldman, Moshe ^a   Kanterman, Julia ^a   Wang, Lynn ^a   Mizrahi, Olga ^b   Klieger, Yair ^a,b   Baniyash, Michal ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b ImProDia Ltd   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD3 ANTIGEN, ZETA CHAIN; SNX9 PROTEIN, HUMAN; SORTING NEXIN; TUMOR MARKER;

ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; BONE MARROW CELL; C57BL MOUSE; CELL CULTURE; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DBA MOUSE; DISEASE MODEL; FEMALE; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; INFLAMMATION; LEISHMANIA DONOVANI; MALE; MELANOMA; MOUSE; PARASITOLOGY; PATHOLOGY; RHEUMATOID ARTHRITIS; TH1 CELL; TH2 CELL; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIGENS, CD3; ARTHRITIS, RHEUMATOID; BIOMARKERS, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INFLAMMATION; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MALE; MELANOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; MYELOID CELLS; SORTING NEXINS; TH1 CELLS; TH2 CELLS;

EID: 84953264688     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402877     Document Type: Article

References (50)

1. Baniyash, M. 2004. TCR ζ-chain downregulation: curtailing an excessive inflammatory immune response. Nat. Rev. Immunol. 4: 675-687.
2. Baniyash, M. 2006. Chronic inflammation, immunosuppression and cancer: new insights and outlook. Semin. Cancer Biol. 16: 80-88.
3. Ezernitchi, A. V., I. Vaknin, L. Cohen-Daniel, O. Levy, E. Manaster, A. Halabi, E. Pikarsky, L. Shapira, and M. Baniyash. 2006. TCR t, down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J. Immunol. 177: 4763-41772.
4. Vaknin, I., L. Blinder, L. Wang, R. Gazit, E. Shapira, O. Genina, M. Pines, E. Pikarsky, and M. Baniyash. 2008. A common pathway mediated through Tolllike receptors leads to T- and natural killer-cell immunosuppression. Blood 111: 1437-1447.
5. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
6. Ostrand-Rosenberg, S., and P Sinha. 2009. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182: 4499-41506.
7. Serafmi, P, I. Borrello, and V. Bronte. 2006. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 16: 53-65.
8. Lawrence, T, and D. W. Gilroy. 2007. Chronic inflammation: a failure of resolution? Int. J. Exp. Pathol. 88: 85-94.
9. Cuenca, A. G., M. J. Delano, K. M. Kelly-Scumpia, C. Moreno, P. O. Scumpia, D. M. Laface, P. G. Heyworth, P. A. Efron, and L. L. Moldawer. 2011. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol. Med. 17: 281-292.
10. Yu, B., and W. Zhang. 2011. Down-regulation of CD3ζ is a breast cancer biomarker associated with immune suppression. Cell Biol. Int. 35: 165-169.
11. MaCaulay, S. L., V. Stoichevska, J. Grusovin, K. H. Gough, L. A. Castelli, and C. W. Ward. 2003. Insulin stimulates movement of sorting nexin 9 between cellular compartments: a putative role mediating cell surface receptor expression and insulin action. Biochem. J. 376: 123-134.
12. Haberg, K., R. Lundmark, and S. R. Carlsson. 2008. SNX18 is an SNX9 paralog that acts as a membrane tubulator in AP-1 -positive endosomal trafficking. J. Cell Sci. 121: 1495-1505.
13. Wang, I. T, M. C. Kerr, S. Karunaratne, A. leanes, A. S. Yap, and R. D. Teasdale. 2010. The SNX-PX-BAR family in macropinocytosis: the regulation of macropinosome formation by SNX-PX-BAR proteins. PLoS One 5: el3763.
14. Shin, N., S. Lee, N. Ahn, S. A. Kim, S. G. Ahn, Z. YongPark, and S. Chang. 2007. Sorting nexin 9 interacts with dynamin 1 and N-WASP and coordinates synaptic vesicle endocytosis. J. Biol. Chem. 282: 28939-28950.
15. Lundmark, R., and S. R. Carlsson. 2003. Sorting nexin 9 participates in clathrin-mediated endocytosis through interactions with the core components. J. Biol. Chem. 278: 46772-46781.
16. Badour, K., M. K McGavin, I. Zhang, S. Freeman, C. Vieira, D. Filipp, M. lulius, G. B. Mills, and K. A. Siminovitch. 2007. Interaction of the Wiskott-Aldrich syndrome protein with sorting nexin 9 is required for CD28 endocytosis and cosignaling in T cells. Proc. Natl. Acad. Sci. USA 104: 1593-1598.
17. Sade-Feldman, M., J. Kanterman, E. Ish-Shalom, M. Elnekave, E. Horwitz, and M. Baniyash. 2013. Tumor necrosis factor-a blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity 38: 541-554.
18. Bronstein-Sitton, N., L. Cohen-Daniel, I. Vaknin, A. V Ezernitchi, B. Leshem, A. Halabi, Y Houri-Hadad, E. Greenbaum, Z. Zakay-Rones, L. Shapira, and M. Baniyash. 2003. Sustained exposure to bacterial antigen induces interferon-7-dependent T cell receptor t, down-regulation and impaired T cell function. Nat. Immunol. 4: 957-964.
19. Nedvetzki, S., M. Walmsley, E. Alpert, R. O. Williams, M. Feldmann, and D. Naor. 1999. CD44 involvement in experimental collagen-induced arthritis (CIA). J. Autoimmun. 13: 39-417.
20. Goto, H., and J. A. Lindoso. 2004. Immunity and immunosuppression in experimental visceral leishmaniasis. Braz. J. Med. Biol. Res. 37: 615-623.
21. Kanterman, J., M. Sade-Feldman, M. Biton, E. Ish-Shalom, A. Lasry, A. Goldshtein, A. Hubert, and M. Baniyash. 2014. Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes. Cancer Res. 14: 6022-6035.
22. Goldberger, O., I. Volovitz, A. Machlenkin, E. Vadai, E. Tzehoval, and L. Eisenbach. 2008. Exuberated numbers of tumor-specific T cells result in tumor escape. Cancer Res. 68: 3450-3457.
23. Liu, X. P., S. T. Zhou, X. Y. Li, X. C. Chen, X. Zhao, Z. Y. Qian, L. N. Zhou, Z. Y. Li, Y. M. Wang, Q. Zhong, et al. 2010. Anti-tumor activity of JV-trimethyl chitosan-encapsulated camptothecin in a mouse melanoma model. J. Exp. Clin. Cancer Res. 29: 76.
24. Caplan, S., S. Zeliger, L. Wang, and M. Baniyash. 1995. Cell-surface-expressed T-cell antigen-receptor t, chain is associated with the cytoskeleton. Proc. Natl. Acad. Sci. USA 92: 4168-4112.
25. Herberman, R. B. 1972. Serological analysis of cell surface antigens of tumors induced by murine leukemia virus. J. Natl. Cancer Inst. 48: 265-271.
26. Klieger, Y., O. Almogi-Hazan, E. Ish-Shalom, A. Pato, M. H. Pauker, M. Barda-Saad, L. Wang, and M. Baniyash. 2014. Unique ζ-chain motifs mediate a direct TCR-actin linkage critical for immunological synapse formation and T-cell activation. Eur. J. Immunol. 44: 58-68.
27. Lundmark, R., and S. R. Carlsson. 2009. SNX9-a prelude to vesicle release. J. Cell Sci. 122: 5-11.
28. Czuprynski, C. J., J. F. Brown, N. Maroushek, R. D. Wagner, and H. Steinberg. 1994. Administration of anti-granulocyte mAb RB6-8C5 impairs the resistance of mice to Listeria monocytogenes infection. J. Immunol. 152: 1836-1846.
29. Kappler, J., J. White, D. Wegmann, E. Mustain, and P. Marrack. 1982. Antigen presentation by Ia+ B cell hybridomas to H-2-restricted T cell hybridomas. Proc. Natl. Acad. Sci. USA 79: 3604-3607.
30. Okayasu, I., T. Ohkusa, K. Kajiura, J. Kanno, and S. Sakamoto. 1996. Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut 39: 87-92.
31. Becker, J. C, R. Houben, D. Schrama, H. Voigt, S. Ugurel, and R. A. Reisfeld. 2010. Mouse models for melanoma: a personal perspective. Exp. Dermatol. 19: 157-164.
32. Fidler, I. J., and G. L. Nicolson. 1976. Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J. Natl. Cancer Inst. 57: 1199-1202.
33. Vincent, J., G. Mignot, F. Chalmin, S. Ladoire, M. Bruchard, A. Chevriaux, F. Martin, L. Apetoh, C. Rebe, and F. Ghiringhelli. 2010. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70: 3052-3061.
34. Bronte, V., and P. Zanovello. 2005. Regulation of immune responses by l-ar-ginine metabolism. Nat. Rev. Immunol. 5: 641-654.
35. Rodriguez, P. C, and A. C. Ochoa. 2008. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol. Rev. 222: 180-191.
36. Milsom, C, J. Yu, L. May, B. Meehan, N. Magnus, K. Al-Nedawi, J. Luyendyk, J. Weitz, P. Klement, G. Broze, et al. 2007. The role of tumor-and host-related tissue factor pools in oncogene-driven tumor progression. Thromb. Res. 120 (Suppl. 2): S82-S91.
37. Reichert, T. E., L. Strauss, E. M. Wagner, W. Gooding, and T. L. Whiteside. 2002. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin. Cancer Res. 8: 3137-3145.
38. Mizoguchi, H., J. J. O'Shea, D. L. Longo, C. M. Loeffler, D. W. McVicar, and A. C. Ochoa. 1992. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258: 1795-1798.
39. Lai, P., H. Rabinowich, P. A. Crowley-Nowick, M. C. Bell, G. Mantovani, and T. L. Whiteside. 1996. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin. Cancer Res. 2: 161-173.
40. -T cells have signalling defects in patients with squamous cell carcinoma of the head and neck. Br. J. Cancer 88: 223-230.
41. Ray, A., K. Chakraborty, and P. Ray. 2013. Immunosuppressive MDSCs induced by TLR signaling during infection and role in resolution of inflammation. Front. Cell. Infect. Microbiol. 3: 52.
42. Kanterman, J., M. Sade-Feldman, and M. Baniyash. 2012. New insights into chronic inflammation-induced immunosuppression. Semin. Cancer Biol. 22: 307-318.
43. Monoranu, C. M., B. Huang, I. L. Zangen, S. Rutkowski, G. H. Vince, N. U. Gerber, B. Puppe, and W. Roggendorf. 2008. Correlation between 6q25.3 deletion status and survival in pediatric intracranial ependymomas. Cancer Genet. Cytogenet. 182: 18-26.
44. Sun, H. S., I. J. Su, Y. C. Lin, J. S. Chen, and S. Y. Fang. 2003. A 2.6 Mb interval on chromosome 6q25.2-q25.3 is commonly deleted in human nasal natural killer/T-cell lymphoma. Br. J. Haematol. 122: 590-599.
45. Mao, X., L. K. Boyd, R. J. Yanez-Munoz, T. Chaplin, L. Xue, D. Lin, L. Shan, D. M. Berney, B. D. Young, and Y. J. Lu. 2011. Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer. Am. J. Cancer Res. 1: 604-617.
46. Ma, M. P., and M. Chircop. 2012. SNX9, SNX18 and SNX33 are required for progression through and completion of mitosis. J. Cell Sci. 125: 4372-44382.
47. Osborne, D. G, J. T. Piotrowski, C. J. Dick, J. S. Zhang, and D. D. Billadeau. 2015. SNX17 affects T cell activation by regulating TCR and integrin recycling. J. Immunol. 194: 4555-4566.
48. Rincon, E., J. Saez de Guinoa, S. I. Gharbi, C. O. Sorzano, Y. R. Carrasco, and I. Merida. 2011. Translocation dynamics of sorting nexin 27 in activated T cells. J. Cell Sci. 124: 776-788.
49. Scott, D. L., and S. Steer. 2007. The course of established rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 21: 943-967.
50. Park, J., Y. Kim, S. Lee, J. J. Park, Z. Y. Park, W. Sun, H. Kim, and S. Chang. 2010. SNX18 shares a redundant role with SNX9 and modulates endocytic trafficking at the plasma membrane. J. Cell Sci. 123: 1742-1750.